{
    "clinical_study": {
        "@rank": "102691", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. The subjects will be fasting from the prior midnight to four hours post-dose."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging efficacy and safety data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will receive GSK2798745 following a standard high fat/high calorie meal. In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 3, subjects will receive a capsule formulation of GSK2798745 under fasting conditions"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Doses and food intake timing will be determined based on data from Cohorts 1 and 2. Doses will be administered once daily from Day 1 to Day14 (inclusive). Dosing may be altered to twice daily based on the results obtained in Cohorts 1 and 2."
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "Fifteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 12:3. The subjects will receive GSK2798745 in a single dose followed by a 7-day repeat dose. Dose determination and decision of food intake timing will be determined based on results from Cohorts 1 to 3. The highest safe and well tolerated dose will be administered."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is the first administration of GSK2798745 in humans. This will be a single\n      centre, sponsor un-blinded, placebo-controlled study to investigate the safety,\n      tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2798745, given as\n      single and repeat oral doses to healthy subjects and stable heart failure (HF) subjects.\n      Approximately 36 healthy subjects will be enrolled in the study cohorts (Cohort 1-3)\n      involving single and repeat dose escalations of GSK2798745, while 15 stable heart failure\n      subjects will be enrolled in Cohort 4 involving single and repeat dose administration of\n      GSK2798745, with the dose selected based on data from healthy subject cohorts. The study\n      duration, including screening and follow-up, is not expected to exceed 120 days for subjects\n      in the study (in any cohort)."
        }, 
        "brief_title": "A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Oedema, Pulmonary", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Pulmonary Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        For Healthy Subject Cohorts (1-3):\n\n          -  Male or female 18-75 years of age inclusive, at the time of signing the informed\n             consent.\n\n          -  Healthy as determined by a responsible and experienced physician, based on an\n             evaluation including medical history, physical examination, laboratory tests and\n             cardiac evaluation including ECG and echocardiogram. A subject with a clinical\n             abnormality or laboratory parameter(s) which is/are not specifically listed in the\n             inclusion or exclusion criteria, outside the reference range for the population being\n             studied may be included only if the Investigator in consultation with the GSK Medical\n             Monitor agree and document that the finding is unlikely to introduce additional risk\n             factors and will not interfere with the study procedures.\n\n          -  Body weight >=50 kilogram (kg) and Body Mass Index (BMI) within the range 18-32\n             kilogram/ square meter (kg/m^2) (inclusive).\n\n          -  A female subject is eligible to participate if she is of Non-childbearing potential\n             defined as pre-menopausal females with a documented tubal ligation or hysterectomy\n             for this definition, \"documented\" refers to the outcome of the\n             Investigator's/designee's review of the subject's medical history for study\n             eligibility, as obtained via a verbal interview with the subject or from the\n             subject's medical records; or postmenopausal defined as 12 months of spontaneous\n             amenorrhea. In questionable cases a blood sample with simultaneous follicle\n             stimulating hormone (FSH) > 40 milli-International Units per milliliter mIU/mL and\n             estradiol <40 picogram/millilitre (pg/mL) [<147 picomoles/liter (pmol/L)] is\n             confirmatory.\n\n          -  Male subjects with female partners of child-bearing potential must agree to use a\n             contraception method as per the protocol. This criterion must be followed from the\n             time of the first dose of study medication until 2 weeks post last dose.\n\n          -  Capable of giving written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form.\n\n          -  Alanine transaminase (ALT), alkaline phosphatase and bilirubin <= 1.5x Upper limit of\n             normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated\n             and direct bilirubin <35%).\n\n          -  Based on averaged QTc values of triplicate ECGs obtained over a brief recording\n             period: QTc <450 milliseconds (msec); or QTc <480 msec in subjects with Bundle Branch\n             Block.\n\n        For Heart Failure Subjects (Cohort 4):\n\n          -  Established diagnosis of mild or moderate heart failure of any aetiology with\n             symptoms defined as corresponding to the New York Heart Association (NYHA) Class II\n             or III on stable heart failure therapy for at least 3 months and was not hospitalized\n             for HF for the last three months.\n\n          -  Male or female 18 years or older, age inclusive, at the time of signing the informed\n             consent.\n\n          -  ALT, alkaline phosphatase and bilirubin <=1.5xULN (isolated bilirubin >1.5xULN is\n             acceptable if bilirubin is fractionated and direct bilirubin <35%).\n\n          -  Based on averaged QTc values of triplicate ECGs obtained over a brief recording\n             period: QTc <450msec; or QTc <480msec in subjects with Bundle Branch Block.\n\n          -  Female subject is eligible to participate if she is of: Non-childbearing potential\n             defined as pre-menopausal females with a documented tubal ligation or hysterectomy\n             for this definition, \"documented\" refers to the outcome of the\n             Investigator's/designee's review of the subject's medical history for study\n             eligibility, as obtained via a verbal interview with the subject or from the\n             subject's medical records; or postmenopausal defined as 12 months of spontaneous\n             amenorrhea. In questionable cases a blood sample with simultaneous follicle\n             stimulating hormone (FSH) >40mIU/mL and estradiol <40pg/mL (<147pmol/L) is\n             confirmatory.\n\n          -  Male subjects with female partners of child-bearing potential must agree to use one\n             of the contraception methods listed in the protocol. This criterion must be followed\n             from the time of the first dose of study medication until 2 weeks post-last dose.\n\n          -  Body weight >=50kg and BMI within the range 18-32kg/m^2 (inclusive).\n\n          -  Capable of giving written informed consent, which includes compliance with the\n             requirements and restrictions listed in the consent form.\n\n        Exclusion Criteria:\n\n          -  Current or chronic history of liver disease, or known hepatic or biliary\n             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n\n          -  Chronic angina, unstable angina, or history of acute coronary syndromes, coronary\n             angioplasty, or stenting within the past 6 months.\n\n          -  History of regular alcohol consumption within 6 months of the study defined as an\n             average weekly intake of >21 units for males or >14 units for females. One unit is\n             equivalent to 8 gram (g) of alcohol: a half-pint (approximately 240mL) of beer, 1\n             glass (125mL) of wine or 1 (25mL) measure of spirits.\n\n          -  History of sensitivity to any of the study medications, or components thereof or a\n             history of drug or other allergy that, in the opinion of the Investigator and/or GSK\n             Medical Monitor, contraindicates their participation.\n\n          -  History of seizure disorder and or stroke.\n\n          -  History of active ulcer disease or gastrointestinal (GI) bleeding.\n\n          -  Current smokers.\n\n          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody\n             result within 3 months of screening.\n\n          -  A positive pre-study drug/alcohol screen.\n\n          -  A positive test for human immunodeficiency virus (HIV) antibody.\n\n          -  A screening cardiac Troponin (cTn) level >ULN.\n\n          -  Baseline presence of severe aortic stenosis.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product within the following time period prior to the first dosing day in the current\n             study: 30 days, 5 half-lives or twice the duration of the biological effect of the\n             investigational product (whichever is longer).\n\n          -  Exposure to more than four new chemical entities within 12 months prior to the first\n             dosing day.\n\n          -  Subjects who are taking >= 20 milligrams (mg) of any statin (HF subjects only).\n\n          -  Left ventricular ejection fraction <50% - (Healthy subjects only).\n\n          -  Subject who, in the Investigator/designee's judgement, poses a significant suicide\n             risk. Evidence of serious suicide risk may include any history of suicidal behaviour\n             and/or any evidence of suicidal ideation on any questionnaires e.g., Type 4 or 5 on\n             the Columbia Suicide Severity Rating Scale (C-SSRS) in the last 5 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119260", 
            "org_study_id": "117387"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 3", 
                    "Cohort 2", 
                    "Cohort 1", 
                    "Cohort 4"
                ], 
                "description": "Clear, colourless GSK2798745 (0.1-0.4mg) solution in aqueous citrate buffer with 4% captisol", 
                "intervention_name": "GSK2798745 solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 3", 
                    "Cohort 2", 
                    "Cohort 1", 
                    "Cohort 4"
                ], 
                "description": "Aqueous suspension of GSK2798745 (>=0.5 mg)", 
                "intervention_name": "GSK2798745 suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 3", 
                    "Cohort 2", 
                    "Cohort 4"
                ], 
                "description": "White Opaque granule filled capsules of GSK2798745 (2.5-4.0 mg)", 
                "intervention_name": "GSK2798745 capsule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 3", 
                    "Cohort 1", 
                    "Cohort 4"
                ], 
                "description": "Clear, colourless solution of aqueous citrate buffer with 4% captisol", 
                "intervention_name": "Placebo solution", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 3", 
                    "Cohort 1", 
                    "Cohort 4"
                ], 
                "description": "Visually matching aqueous suspension of hypromellose acetate succinate powder", 
                "intervention_name": "Placebo suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 3", 
                    "Cohort 4"
                ], 
                "description": "Matching White Opaque granule filled placebo capsule", 
                "intervention_name": "Placebo capsule", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "First Time in Human", 
            "TRPV4 inhibitor", 
            "Heart failure"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Single-Centre, Sponsor Un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Vital sign measurements will include systolic and diastolic blood pressure, heart rate, and respiratory rate", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by vital signs", 
                "safety_issue": "No", 
                "time_frame": "Approximately 45 days"
            }, 
            {
                "description": "Vital sign measurements will include systolic and diastolic blood pressure, heart rate, and respiratory rate", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by vital signs", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 days"
            }, 
            {
                "description": "Continuous cardiac telemetry will be performed using a telemeter monitor", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by telemetry monitoring", 
                "safety_issue": "No", 
                "time_frame": "2 days"
            }, 
            {
                "description": "Continuous cardiac telemetry will be performed using a telemeter monitor", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by telemetry monitoring", 
                "safety_issue": "No", 
                "time_frame": "2 days"
            }, 
            {
                "description": "Twelve-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be measured after resting in semi-supine position for 5 minutes", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by electrocardiogram (ECG)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 45 days"
            }, 
            {
                "description": "Twelve-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be measured after resting in semi-supine position for 5 minutes", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by ECG", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 days"
            }, 
            {
                "description": "Clinical laboratory tests include hematology, clinical chemistry, urinalysis and additional parameters", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by clinical laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "Approximately 45 days"
            }, 
            {
                "description": "Clinical laboratory tests include hematology, clinical chemistry, urinalysis and additional parameters", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by clinical laboratory tests", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 days"
            }, 
            {
                "description": "AEs will be collected from the start of study treatment and until the follow-up contact", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by adverse events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 45 days"
            }, 
            {
                "description": "AEs will be collected from the start of study treatment and until the follow-up contact", 
                "measure": "Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by AEs", 
                "safety_issue": "No", 
                "time_frame": "Approximately 30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "From the plasma concentration-time data, the following PK parameters will be determined, as data permit: maximum observed plasma concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration-time curve [AUC (0-t) and AUC (0-infinity)], and apparent terminal phase half-life (t1/2)", 
                "measure": "Composite of pharmacokinetic (PK) parameters following single and repeat dose administration of GSK2798745 in healthy subjects", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3 and 4 for single dose; and Days 1, 2, 3, 4, 7, 10, 14, 15, 16 and 17 for repeat dose"
            }, 
            {
                "description": "From the plasma concentration-time data, the following PK parameters will be determined, as data permit: Cmax, Tmax, AUC (0-t) and AUC (0-infinity), and t1/2", 
                "measure": "Composite of PK parameters following single and repeat dose administration of GSK2798745 in stable HF subjects", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3 and 4 for single dose; and Days 1, 2, 3, 4, 6, 8, 9 and 10 for repeat dose"
            }, 
            {
                "description": "Effect of food on PK will be assessed by comparing AUC and Cmax values in fed and fasted state", 
                "measure": "Composite of PK parameters following single dose of GSK2798745 in fed and fasted state", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3 and 4"
            }, 
            {
                "description": "From the plasma concentration-time data, the following PK parameters will be determined, as data permit: Cmax, Tmax, AUC (0-t) and AUC (0-infinity), and t1/2", 
                "measure": "Composite of PK parameters following single dose of GSK2798745 liquid or capsule formulations", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 2, 3 and 4"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}